Clinical Edge Journal Scan

Key clinical point: The addition of abemaciclib to endocrine therapy (ET) demonstrated robust treatment benefits regardless of menopausal status in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), high-risk early breast cancer (BC).

Major finding: Abemaciclib+ET significantly improved invasive disease-free survival (iDFS; hazard ratio 0.785; nominal P = .0268) in postmenopausal women with HR+/HER2− BC and led to even greater iDFS improvement (hazard ratio 0.578; P < .0001) in premenopausal women. No new safety events were reported.

Study details: Findings are from an exploratory analysis of the monarchE trial including 5637 patients with HR+/HER2−, node-positive, high-risk early BC who were randomly assigned to receive standard of care ET with/without adjuvant abemaciclib, of which 43.5% and 56.4% of patients were premenopausal and postmenopausal, respectively.

Disclosures: This study was funded by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly. The other authors reported ties with several sources, including Eli Lilly.

Source: Paluch-Shimon S et al, on behalf of the monarchE investigators. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer. Ther Adv Med Oncol. 2023 (Feb 3). Doi: 10.1177/17588359231151840

Key clinical point: The addition of abemaciclib to endocrine therapy (ET) demonstrated robust treatment benefits regardless of menopausal status in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), high-risk early breast cancer (BC).

Major finding: Abemaciclib+ET significantly improved invasive disease-free survival (iDFS; hazard ratio 0.785; nominal P = .0268) in postmenopausal women with HR+/HER2− BC and led to even greater iDFS improvement (hazard ratio 0.578; P < .0001) in premenopausal women. No new safety events were reported.

Study details: Findings are from an exploratory analysis of the monarchE trial including 5637 patients with HR+/HER2−, node-positive, high-risk early BC who were randomly assigned to receive standard of care ET with/without adjuvant abemaciclib, of which 43.5% and 56.4% of patients were premenopausal and postmenopausal, respectively.

Disclosures: This study was funded by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly. The other authors reported ties with several sources, including Eli Lilly.

Source: Paluch-Shimon S et al, on behalf of the monarchE investigators. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer. Ther Adv Med Oncol. 2023 (Feb 3). Doi: 10.1177/17588359231151840

Key clinical point: The addition of abemaciclib to endocrine therapy (ET) demonstrated robust treatment benefits regardless of menopausal status in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), high-risk early breast cancer (BC).

Major finding: Abemaciclib+ET significantly improved invasive disease-free survival (iDFS; hazard ratio 0.785; nominal P = .0268) in postmenopausal women with HR+/HER2− BC and led to even greater iDFS improvement (hazard ratio 0.578; P < .0001) in premenopausal women. No new safety events were reported.

Study details: Findings are from an exploratory analysis of the monarchE trial including 5637 patients with HR+/HER2−, node-positive, high-risk early BC who were randomly assigned to receive standard of care ET with/without adjuvant abemaciclib, of which 43.5% and 56.4% of patients were premenopausal and postmenopausal, respectively.

Disclosures: This study was funded by Eli Lilly and Company. Four authors declared being employees and shareholders of Eli Lilly. The other authors reported ties with several sources, including Eli Lilly.

Source: Paluch-Shimon S et al, on behalf of the monarchE investigators. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer. Ther Adv Med Oncol. 2023 (Feb 3). Doi: 10.1177/17588359231151840

Key clinical point: In patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC), adding endocrine therapy (ET) to dual anti-HER2 targeted therapy after chemotherapy improved progression-free survival (PFS) without increasing the rate of adverse events.

Major finding: There was a significant improvement in 5-year PFS with vs without the addition of ET (hazard ratio 0.59; P = .031). Nausea and vomiting were more common in patients who did not vs did receive ET (21% vs 7%; P = .010).

Study details: This study analyzed the real-world data of 147 patients with HER2+/HR+ metastatic BC from a prospective registry who received first-line chemotherapy plus trastuzumab and pertuzumab with (n = 91) or without (n = 56) concurrent ET.

Disclosures: This study did not receive any funding. Some authors declared serving on the advisory board for or receiving research funding, speaker honoraria, or travel grants from several sources.

Source: Loft M et al. Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. Breast Cancer Res Treat. 2023;198:67-74 (Jan 9). Doi: 10.1007/s10549-022-06856-1

Key clinical point: In patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC), adding endocrine therapy (ET) to dual anti-HER2 targeted therapy after chemotherapy improved progression-free survival (PFS) without increasing the rate of adverse events.

Major finding: There was a significant improvement in 5-year PFS with vs without the addition of ET (hazard ratio 0.59; P = .031). Nausea and vomiting were more common in patients who did not vs did receive ET (21% vs 7%; P = .010).

Study details: This study analyzed the real-world data of 147 patients with HER2+/HR+ metastatic BC from a prospective registry who received first-line chemotherapy plus trastuzumab and pertuzumab with (n = 91) or without (n = 56) concurrent ET.

Disclosures: This study did not receive any funding. Some authors declared serving on the advisory board for or receiving research funding, speaker honoraria, or travel grants from several sources.

Source: Loft M et al. Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. Breast Cancer Res Treat. 2023;198:67-74 (Jan 9). Doi: 10.1007/s10549-022-06856-1

Key clinical point: In patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (BC), adding endocrine therapy (ET) to dual anti-HER2 targeted therapy after chemotherapy improved progression-free survival (PFS) without increasing the rate of adverse events.

Major finding: There was a significant improvement in 5-year PFS with vs without the addition of ET (hazard ratio 0.59; P = .031). Nausea and vomiting were more common in patients who did not vs did receive ET (21% vs 7%; P = .010).

Study details: This study analyzed the real-world data of 147 patients with HER2+/HR+ metastatic BC from a prospective registry who received first-line chemotherapy plus trastuzumab and pertuzumab with (n = 91) or without (n = 56) concurrent ET.

Disclosures: This study did not receive any funding. Some authors declared serving on the advisory board for or receiving research funding, speaker honoraria, or travel grants from several sources.

Source: Loft M et al. Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer. Breast Cancer Res Treat. 2023;198:67-74 (Jan 9). Doi: 10.1007/s10549-022-06856-1

Key clinical point: Marking sentinel lymph nodes (SLN) with superparamagnetic iron oxide (SPIO) nanoparticles led to a substantial proportion of patients with ductal carcinoma in situ (DCIS) of the breast avoiding an upfront SLN dissection (SLND).

Major finding: Upfront SLND could be avoided in 78.3% of patients after marking SLN with SPIO nanoparticles. Among patients receiving delayed SLND, the detection rate was significantly better with SPIO vs radioisotope (⁹⁹Tc), both with (98.2% vs 63.6%) and without the concomitant use of blue dye (92.7% vs 50.9%; both P < .001).

Study details: Findings are from a prospective, multicenter cohort study including 254 patients with DCIS.

Disclosures: This study was funded by the Uppsala University. One author declared serving on an advisory board and receiving institutional grants and speaker honoraria from several sources.

Source: Karakatsanis A et al. Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: The SentiNot study. Ann Surg Oncol. 2023 (Jan 31). Doi: 10.1245/s10434-022-13064-0

Key clinical point: Marking sentinel lymph nodes (SLN) with superparamagnetic iron oxide (SPIO) nanoparticles led to a substantial proportion of patients with ductal carcinoma in situ (DCIS) of the breast avoiding an upfront SLN dissection (SLND).

Major finding: Upfront SLND could be avoided in 78.3% of patients after marking SLN with SPIO nanoparticles. Among patients receiving delayed SLND, the detection rate was significantly better with SPIO vs radioisotope (⁹⁹Tc), both with (98.2% vs 63.6%) and without the concomitant use of blue dye (92.7% vs 50.9%; both P < .001).

Study details: Findings are from a prospective, multicenter cohort study including 254 patients with DCIS.

Disclosures: This study was funded by the Uppsala University. One author declared serving on an advisory board and receiving institutional grants and speaker honoraria from several sources.

Source: Karakatsanis A et al. Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: The SentiNot study. Ann Surg Oncol. 2023 (Jan 31). Doi: 10.1245/s10434-022-13064-0

Key clinical point: Marking sentinel lymph nodes (SLN) with superparamagnetic iron oxide (SPIO) nanoparticles led to a substantial proportion of patients with ductal carcinoma in situ (DCIS) of the breast avoiding an upfront SLN dissection (SLND).

Major finding: Upfront SLND could be avoided in 78.3% of patients after marking SLN with SPIO nanoparticles. Among patients receiving delayed SLND, the detection rate was significantly better with SPIO vs radioisotope (⁹⁹Tc), both with (98.2% vs 63.6%) and without the concomitant use of blue dye (92.7% vs 50.9%; both P < .001).

Study details: Findings are from a prospective, multicenter cohort study including 254 patients with DCIS.

Disclosures: This study was funded by the Uppsala University. One author declared serving on an advisory board and receiving institutional grants and speaker honoraria from several sources.

Source: Karakatsanis A et al. Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: The SentiNot study. Ann Surg Oncol. 2023 (Jan 31). Doi: 10.1245/s10434-022-13064-0

Key clinical point: Contralateral prophylactic mastectomy (CPM) did not offer any survival benefit to patients with triple-negative breast cancer (TNBC) irrespective of the presence of BRCA mutations.

Major finding: The 5-year overall survival did not significantly improve with vs without CPM in the entire population of patients with TNBC (P = .05) and in the subgroups of patients with (P = .35) and without (P = .12) BRCA mutations.

Study details: Findings are from a multi-institutional database study including 796 patients with TNBC, of which 15.5% of patients underwent CPM.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Fasano GA et al. Survival outcomes in women with unilateral, triple-negative, breast cancer correlated with contralateral prophylactic mastectomy. Ann Surg Oncol. 2023 (Jan 21). Doi: 10.1245/s10434-022-13056-0

Key clinical point: Contralateral prophylactic mastectomy (CPM) did not offer any survival benefit to patients with triple-negative breast cancer (TNBC) irrespective of the presence of BRCA mutations.

Major finding: The 5-year overall survival did not significantly improve with vs without CPM in the entire population of patients with TNBC (P = .05) and in the subgroups of patients with (P = .35) and without (P = .12) BRCA mutations.

Study details: Findings are from a multi-institutional database study including 796 patients with TNBC, of which 15.5% of patients underwent CPM.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Fasano GA et al. Survival outcomes in women with unilateral, triple-negative, breast cancer correlated with contralateral prophylactic mastectomy. Ann Surg Oncol. 2023 (Jan 21). Doi: 10.1245/s10434-022-13056-0

Key clinical point: Contralateral prophylactic mastectomy (CPM) did not offer any survival benefit to patients with triple-negative breast cancer (TNBC) irrespective of the presence of BRCA mutations.

Major finding: The 5-year overall survival did not significantly improve with vs without CPM in the entire population of patients with TNBC (P = .05) and in the subgroups of patients with (P = .35) and without (P = .12) BRCA mutations.

Study details: Findings are from a multi-institutional database study including 796 patients with TNBC, of which 15.5% of patients underwent CPM.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Fasano GA et al. Survival outcomes in women with unilateral, triple-negative, breast cancer correlated with contralateral prophylactic mastectomy. Ann Surg Oncol. 2023 (Jan 21). Doi: 10.1245/s10434-022-13056-0

Key clinical point: Adjuvant endocrine therapy (ET) with an aromatase inhibitor (AI) was associated with better disease-free survival (DFS) than tamoxifen-only or tamoxifen+AI in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor2-positive (HER2+) breast cancer (BC).

Major finding: Adjuvant ET with tamoxifen or tamoxifen+AI was associated with significantly worse DFS rates than AI in the entire population of women with HR+/HER2+ BC (hazard ratio 1.64; P = .025), with gonadotropin-releasing hormone being associated with improved DFS rates in premenopausal patients aged ≤45 years (hazard ratio 0.41; P = .023).

Study details: Findings are from a post hoc analysis of the ShortHER trial including 784 patients with HR+/HER2+ early BC who received adjuvant anthracycline/taxane-based chemotherapy plus trastuzumab.

Disclosures: This study was supported by Agenzia Italiana del Farmaco and other sources. Some authors declared receiving personal fees from several sources.

Source: Dieci MV et al. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: Analysis from the phase III randomized ShortHER trial. NPJ Breast Cancer. 2023;9(1):6 (Feb 4). Doi: 10.1038/s41523-023-00509-2

Key clinical point: Adjuvant endocrine therapy (ET) with an aromatase inhibitor (AI) was associated with better disease-free survival (DFS) than tamoxifen-only or tamoxifen+AI in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor2-positive (HER2+) breast cancer (BC).

Major finding: Adjuvant ET with tamoxifen or tamoxifen+AI was associated with significantly worse DFS rates than AI in the entire population of women with HR+/HER2+ BC (hazard ratio 1.64; P = .025), with gonadotropin-releasing hormone being associated with improved DFS rates in premenopausal patients aged ≤45 years (hazard ratio 0.41; P = .023).

Study details: Findings are from a post hoc analysis of the ShortHER trial including 784 patients with HR+/HER2+ early BC who received adjuvant anthracycline/taxane-based chemotherapy plus trastuzumab.

Disclosures: This study was supported by Agenzia Italiana del Farmaco and other sources. Some authors declared receiving personal fees from several sources.

Source: Dieci MV et al. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: Analysis from the phase III randomized ShortHER trial. NPJ Breast Cancer. 2023;9(1):6 (Feb 4). Doi: 10.1038/s41523-023-00509-2

Key clinical point: Adjuvant endocrine therapy (ET) with an aromatase inhibitor (AI) was associated with better disease-free survival (DFS) than tamoxifen-only or tamoxifen+AI in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor2-positive (HER2+) breast cancer (BC).

Major finding: Adjuvant ET with tamoxifen or tamoxifen+AI was associated with significantly worse DFS rates than AI in the entire population of women with HR+/HER2+ BC (hazard ratio 1.64; P = .025), with gonadotropin-releasing hormone being associated with improved DFS rates in premenopausal patients aged ≤45 years (hazard ratio 0.41; P = .023).

Study details: Findings are from a post hoc analysis of the ShortHER trial including 784 patients with HR+/HER2+ early BC who received adjuvant anthracycline/taxane-based chemotherapy plus trastuzumab.

Disclosures: This study was supported by Agenzia Italiana del Farmaco and other sources. Some authors declared receiving personal fees from several sources.

Source: Dieci MV et al. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: Analysis from the phase III randomized ShortHER trial. NPJ Breast Cancer. 2023;9(1):6 (Feb 4). Doi: 10.1038/s41523-023-00509-2

Key clinical point: Patients with atopic dermatitis (AD) have an increased risk of developing food allergy (FA), food sensitivity (FS), and challenge-proven food allergy (CPFA), and vice versa.

Major finding: AD was significantly associated with an increased risk for FS (pooled odds ratio [pOR] 4.17; 95% CI 3.03-5.75), FA (pOR 3.91; 95% CI 3.44-4.45), and CPFA (pOR 4.99; 95% CI 2.20-11.35). A significantly increased risk for AD was observed in individuals with FS (pOR 3.92; 95% CI,2.88-5.33), FA (pOR 4.06; 95% CI 3.54-4.65), and CPFA (pOR 4.93; 95% CI 2.74-8.84).

Study details: Findings are from a meta-analysis of 465 studies involving patients with AD (n = 225,568); reference individuals without AD (n = 1,128,322); individuals with FS, FA, and CPFA (n = 1,357,793); and reference individuals without FS, FA, and CPFA (n = 1,244,596).

Disclosures: This study did not receive any funding. Some authors declared serving as advisors, speakers, or consultants for or receiving speaking or consulting fees from various sources.

Source: Christensen MO et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023 (Jan 25). Doi: 10.1111/jdv.18919

Key clinical point: Patients with atopic dermatitis (AD) have an increased risk of developing food allergy (FA), food sensitivity (FS), and challenge-proven food allergy (CPFA), and vice versa.

Major finding: AD was significantly associated with an increased risk for FS (pooled odds ratio [pOR] 4.17; 95% CI 3.03-5.75), FA (pOR 3.91; 95% CI 3.44-4.45), and CPFA (pOR 4.99; 95% CI 2.20-11.35). A significantly increased risk for AD was observed in individuals with FS (pOR 3.92; 95% CI,2.88-5.33), FA (pOR 4.06; 95% CI 3.54-4.65), and CPFA (pOR 4.93; 95% CI 2.74-8.84).

Study details: Findings are from a meta-analysis of 465 studies involving patients with AD (n = 225,568); reference individuals without AD (n = 1,128,322); individuals with FS, FA, and CPFA (n = 1,357,793); and reference individuals without FS, FA, and CPFA (n = 1,244,596).

Disclosures: This study did not receive any funding. Some authors declared serving as advisors, speakers, or consultants for or receiving speaking or consulting fees from various sources.

Source: Christensen MO et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023 (Jan 25). Doi: 10.1111/jdv.18919

Key clinical point: Patients with atopic dermatitis (AD) have an increased risk of developing food allergy (FA), food sensitivity (FS), and challenge-proven food allergy (CPFA), and vice versa.

Major finding: AD was significantly associated with an increased risk for FS (pooled odds ratio [pOR] 4.17; 95% CI 3.03-5.75), FA (pOR 3.91; 95% CI 3.44-4.45), and CPFA (pOR 4.99; 95% CI 2.20-11.35). A significantly increased risk for AD was observed in individuals with FS (pOR 3.92; 95% CI,2.88-5.33), FA (pOR 4.06; 95% CI 3.54-4.65), and CPFA (pOR 4.93; 95% CI 2.74-8.84).

Study details: Findings are from a meta-analysis of 465 studies involving patients with AD (n = 225,568); reference individuals without AD (n = 1,128,322); individuals with FS, FA, and CPFA (n = 1,357,793); and reference individuals without FS, FA, and CPFA (n = 1,244,596).

Disclosures: This study did not receive any funding. Some authors declared serving as advisors, speakers, or consultants for or receiving speaking or consulting fees from various sources.

Source: Christensen MO et al. Prevalence of and association between atopic dermatitis and food sensitivity, food allergy and challenge-proven food allergy: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2023 (Jan 25). Doi: 10.1111/jdv.18919

Key clinical point: In patients with moderate-to-severe atopic dermatitis (AD), itch was more closely associated with patient-reported outcome measures than with objective assessments by the physician.

Major finding: Itch severity had a weak positive correlation with objective Scoring Atopic Dermatitis (rho (ρ) 0.44; 95% CI 0.39-0.48), Eczema Area and Severity Index (ρ 0.41; 95% CI 0.36-0.46), and Investigator Global Assessment (ρ 0.46; 95% CI 0.42-0.51) scores, but a strong positive correlation with Patient Global Assessment score (ρ 0.68; 95% CI 0.65-0.71), Patient-Oriented Eczema Measure sum score (ρ 0.66; 95% CI 0.63-0.69), and Dermatology Life Quality Index score (ρ 0.61; 95% CI 0.57-0.65).

Study details: This study analyzed the data of 1134 adult patients with moderate-to-severe AD from the multicenter prospective TREATgermany registry, of which 1121 had provided data on their itch.

Disclosures: TREATgermany is sponsored by AbbVie Deutschland GmbH & Co. KG, Galderma S.A., and others. Some authors reported ties with various organizations, including TREATgermany sponsors.

Source: Weisshaar E et al. Itching in atopic dermatitis: Patient- and physician-reported outcomes in the German atopic dermatitis registry TREATgermany. Acta Derm Venereol. 2023;103:adv00854 (Jan 23). Doi: 10.2340/actadv.v103.4426

Key clinical point: In patients with moderate-to-severe atopic dermatitis (AD), itch was more closely associated with patient-reported outcome measures than with objective assessments by the physician.

Major finding: Itch severity had a weak positive correlation with objective Scoring Atopic Dermatitis (rho (ρ) 0.44; 95% CI 0.39-0.48), Eczema Area and Severity Index (ρ 0.41; 95% CI 0.36-0.46), and Investigator Global Assessment (ρ 0.46; 95% CI 0.42-0.51) scores, but a strong positive correlation with Patient Global Assessment score (ρ 0.68; 95% CI 0.65-0.71), Patient-Oriented Eczema Measure sum score (ρ 0.66; 95% CI 0.63-0.69), and Dermatology Life Quality Index score (ρ 0.61; 95% CI 0.57-0.65).

Study details: This study analyzed the data of 1134 adult patients with moderate-to-severe AD from the multicenter prospective TREATgermany registry, of which 1121 had provided data on their itch.

Disclosures: TREATgermany is sponsored by AbbVie Deutschland GmbH & Co. KG, Galderma S.A., and others. Some authors reported ties with various organizations, including TREATgermany sponsors.

Source: Weisshaar E et al. Itching in atopic dermatitis: Patient- and physician-reported outcomes in the German atopic dermatitis registry TREATgermany. Acta Derm Venereol. 2023;103:adv00854 (Jan 23). Doi: 10.2340/actadv.v103.4426

Key clinical point: In patients with moderate-to-severe atopic dermatitis (AD), itch was more closely associated with patient-reported outcome measures than with objective assessments by the physician.

Major finding: Itch severity had a weak positive correlation with objective Scoring Atopic Dermatitis (rho (ρ) 0.44; 95% CI 0.39-0.48), Eczema Area and Severity Index (ρ 0.41; 95% CI 0.36-0.46), and Investigator Global Assessment (ρ 0.46; 95% CI 0.42-0.51) scores, but a strong positive correlation with Patient Global Assessment score (ρ 0.68; 95% CI 0.65-0.71), Patient-Oriented Eczema Measure sum score (ρ 0.66; 95% CI 0.63-0.69), and Dermatology Life Quality Index score (ρ 0.61; 95% CI 0.57-0.65).

Study details: This study analyzed the data of 1134 adult patients with moderate-to-severe AD from the multicenter prospective TREATgermany registry, of which 1121 had provided data on their itch.

Disclosures: TREATgermany is sponsored by AbbVie Deutschland GmbH & Co. KG, Galderma S.A., and others. Some authors reported ties with various organizations, including TREATgermany sponsors.

Source: Weisshaar E et al. Itching in atopic dermatitis: Patient- and physician-reported outcomes in the German atopic dermatitis registry TREATgermany. Acta Derm Venereol. 2023;103:adv00854 (Jan 23). Doi: 10.2340/actadv.v103.4426

Key clinical point: Children who were hospitalized for atopic dermatitis (AD) exacerbation had significantly higher serum total IgE levels than those hospitalized for AD-associated infectious complications.

Major finding: Children with AD exacerbation vs an infectious complication had significantly higher mean serum total IgE levels (9603 ± 15,873 vs 3167 ± 5486 kU/L; P = .029). The likelihood of AD exacerbation vs an infectious complication was significantly greater in children with an age-adjusted IgE level (serum total IgE level/maximum reference IgE value for their age) of >4.

Study details: This retrospective chart review study included 68 children hospitalized for AD exacerbations (n = 34) or AD-associated infectious complications (n = 34) over a 17-year period.

Disclosures: This study did not report the source of funding. PY Ong declared serving as a consultant for and receiving research funding from various organizations.

Source: Atwal S, Ong PY. Elevated serum total IgE is associated with eczema exacerbation in children hospitalized for atopic dermatitis. Pediatr Dermatol. 2023 (Jan 19). Doi: 10.1111/pde.15245

Key clinical point: Children who were hospitalized for atopic dermatitis (AD) exacerbation had significantly higher serum total IgE levels than those hospitalized for AD-associated infectious complications.

Major finding: Children with AD exacerbation vs an infectious complication had significantly higher mean serum total IgE levels (9603 ± 15,873 vs 3167 ± 5486 kU/L; P = .029). The likelihood of AD exacerbation vs an infectious complication was significantly greater in children with an age-adjusted IgE level (serum total IgE level/maximum reference IgE value for their age) of >4.

Study details: This retrospective chart review study included 68 children hospitalized for AD exacerbations (n = 34) or AD-associated infectious complications (n = 34) over a 17-year period.

Disclosures: This study did not report the source of funding. PY Ong declared serving as a consultant for and receiving research funding from various organizations.

Source: Atwal S, Ong PY. Elevated serum total IgE is associated with eczema exacerbation in children hospitalized for atopic dermatitis. Pediatr Dermatol. 2023 (Jan 19). Doi: 10.1111/pde.15245

Key clinical point: Children who were hospitalized for atopic dermatitis (AD) exacerbation had significantly higher serum total IgE levels than those hospitalized for AD-associated infectious complications.

Major finding: Children with AD exacerbation vs an infectious complication had significantly higher mean serum total IgE levels (9603 ± 15,873 vs 3167 ± 5486 kU/L; P = .029). The likelihood of AD exacerbation vs an infectious complication was significantly greater in children with an age-adjusted IgE level (serum total IgE level/maximum reference IgE value for their age) of >4.

Study details: This retrospective chart review study included 68 children hospitalized for AD exacerbations (n = 34) or AD-associated infectious complications (n = 34) over a 17-year period.

Disclosures: This study did not report the source of funding. PY Ong declared serving as a consultant for and receiving research funding from various organizations.

Source: Atwal S, Ong PY. Elevated serum total IgE is associated with eczema exacerbation in children hospitalized for atopic dermatitis. Pediatr Dermatol. 2023 (Jan 19). Doi: 10.1111/pde.15245

Key clinical point: Dupilumab demonstrated good 4-year drug survival in patients with moderate-to-severe atopic dermatitis (AD); however, early-onset AD (at <18 years of age) was a risk factor for a shorter drug survival.

Major finding: The 1-, 2-, 3-, and 4-year overall dupilumab drug survival rates were 90.5%, 82.9%, 78.8%, and 76.4%, respectively. Early onset of AD may serve as a significant predictor of shorter overall drug survival (hazard ratio, 1.32; P = .04).

Study details: This real-world prospective cohort study included 363 patients with moderate-to-severe AD who had received dupilumab for ≥4 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants and/or speakers for various organizations.

Source: Pezzolo E et al. Long-term drug survival of dupilumab and associated predictors in moderate to severe atopic dermatitis: A real-world prospective cohort study. J Eur Acad Dermatol Venereol. 2023 (Jan 20). Doi: 10.1111/jdv.18889

Key clinical point: Dupilumab demonstrated good 4-year drug survival in patients with moderate-to-severe atopic dermatitis (AD); however, early-onset AD (at <18 years of age) was a risk factor for a shorter drug survival.

Major finding: The 1-, 2-, 3-, and 4-year overall dupilumab drug survival rates were 90.5%, 82.9%, 78.8%, and 76.4%, respectively. Early onset of AD may serve as a significant predictor of shorter overall drug survival (hazard ratio, 1.32; P = .04).

Study details: This real-world prospective cohort study included 363 patients with moderate-to-severe AD who had received dupilumab for ≥4 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants and/or speakers for various organizations.

Source: Pezzolo E et al. Long-term drug survival of dupilumab and associated predictors in moderate to severe atopic dermatitis: A real-world prospective cohort study. J Eur Acad Dermatol Venereol. 2023 (Jan 20). Doi: 10.1111/jdv.18889

Key clinical point: Dupilumab demonstrated good 4-year drug survival in patients with moderate-to-severe atopic dermatitis (AD); however, early-onset AD (at <18 years of age) was a risk factor for a shorter drug survival.

Major finding: The 1-, 2-, 3-, and 4-year overall dupilumab drug survival rates were 90.5%, 82.9%, 78.8%, and 76.4%, respectively. Early onset of AD may serve as a significant predictor of shorter overall drug survival (hazard ratio, 1.32; P = .04).

Study details: This real-world prospective cohort study included 363 patients with moderate-to-severe AD who had received dupilumab for ≥4 weeks.

Disclosures: This study did not receive any funding. Some authors declared serving as consultants and/or speakers for various organizations.

Source: Pezzolo E et al. Long-term drug survival of dupilumab and associated predictors in moderate to severe atopic dermatitis: A real-world prospective cohort study. J Eur Acad Dermatol Venereol. 2023 (Jan 20). Doi: 10.1111/jdv.18889

Key clinical point: Coadjuvant treatment with a specific probiotic preparation reduced disease severity in children and adolescents with atopic dermatitis (AD), as evidenced by a decrease in Scoring of Atopic Dermatitis (SCORAD) and Investigator’s Global Assessment (IGA) scores.

Major finding: At 12 weeks, patients receiving the probiotic preparation vs placebo had a significantly higher rate of achieving at least a 1-point improvement in IGA score (90.5% vs 56.7%; P < .002) and lower SCORAD score (13.52 vs 18.96; P = .041).

Study details: This study included 70 patients aged 4-17 years with AD who were randomly assigned to receive the probiotic preparation (containing Bifidobacterium lactis, Bifidobacterium longum, and Lactobacillus casei; n = 35) or placebo (n = 35) daily for 12 weeks.

Disclosures: This study was funded by Biopolis SL. The authors declared no conflicts of interest.

Source: Feíto-Rodríguez M et al. Randomised double blind placebo controlled clinical trial to evaluate the effect of a mixture of probiotic strains on symptom severity and the use of corticosteroids in children and adolescents with atopic dermatitis. Clin Exp Dermatol. 2023 (Jan 13). Doi: 10.1093/ced/llad007

Key clinical point: Coadjuvant treatment with a specific probiotic preparation reduced disease severity in children and adolescents with atopic dermatitis (AD), as evidenced by a decrease in Scoring of Atopic Dermatitis (SCORAD) and Investigator’s Global Assessment (IGA) scores.

Major finding: At 12 weeks, patients receiving the probiotic preparation vs placebo had a significantly higher rate of achieving at least a 1-point improvement in IGA score (90.5% vs 56.7%; P < .002) and lower SCORAD score (13.52 vs 18.96; P = .041).

Study details: This study included 70 patients aged 4-17 years with AD who were randomly assigned to receive the probiotic preparation (containing Bifidobacterium lactis, Bifidobacterium longum, and Lactobacillus casei; n = 35) or placebo (n = 35) daily for 12 weeks.

Disclosures: This study was funded by Biopolis SL. The authors declared no conflicts of interest.

Source: Feíto-Rodríguez M et al. Randomised double blind placebo controlled clinical trial to evaluate the effect of a mixture of probiotic strains on symptom severity and the use of corticosteroids in children and adolescents with atopic dermatitis. Clin Exp Dermatol. 2023 (Jan 13). Doi: 10.1093/ced/llad007

Key clinical point: Coadjuvant treatment with a specific probiotic preparation reduced disease severity in children and adolescents with atopic dermatitis (AD), as evidenced by a decrease in Scoring of Atopic Dermatitis (SCORAD) and Investigator’s Global Assessment (IGA) scores.

Major finding: At 12 weeks, patients receiving the probiotic preparation vs placebo had a significantly higher rate of achieving at least a 1-point improvement in IGA score (90.5% vs 56.7%; P < .002) and lower SCORAD score (13.52 vs 18.96; P = .041).

Study details: This study included 70 patients aged 4-17 years with AD who were randomly assigned to receive the probiotic preparation (containing Bifidobacterium lactis, Bifidobacterium longum, and Lactobacillus casei; n = 35) or placebo (n = 35) daily for 12 weeks.

Disclosures: This study was funded by Biopolis SL. The authors declared no conflicts of interest.

Source: Feíto-Rodríguez M et al. Randomised double blind placebo controlled clinical trial to evaluate the effect of a mixture of probiotic strains on symptom severity and the use of corticosteroids in children and adolescents with atopic dermatitis. Clin Exp Dermatol. 2023 (Jan 13). Doi: 10.1093/ced/llad007